Treatment of alarming hemangiomas in infancy: Efficacy and safety of interferon alpha;Efficacite et danger de l'interferon alpha dans le traitement des hemangiomes graves du nourrisson

Archives de Pediatrie

Volumn 7, Issue 2, 2000, Pages 163-167

  Grimal, I ^a   Duveau, E ^a   Enjolras, O ^c   Verret, J L ^b   Ginies J L ^a  

^a Departement de Pédiatrie   (France)

^b ANGERS UNIVERSITY HOSPITAL   (France)

^c Hôpital Cochin ^*  (France)

Author keywords

Hemangioma; Infant, newborn; Interferon alpha; Prednisone; Spastic paraplegia

Indexed keywords

PREDNISONE; RECOMBINANT ALPHA2A INTERFERON; ALPHA2A INTERFERON; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; PREDNISOLONE;

ARTICLE; CASE REPORT; DRUG EFFICACY; DRUG SAFETY; HEMANGIOMA; HUMAN; INFANT; NUCLEAR MAGNETIC RESONANCE IMAGING; SPASTIC PARAPLEGIA; TREATMENT OUTCOME; AMBLYOPIA; CANCER INVASION; FACE TUMOR; FEMALE; FOLLOW UP; HEAD AND NECK TUMOR; INTRAVENOUS DRUG ADMINISTRATION; ORBIT TUMOR; PARAPLEGIA; PATHOPHYSIOLOGY; SAFETY; SUBCUTANEOUS DRUG ADMINISTRATION;

AMBLYOPIA; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; FACIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HEMANGIOMA; HUMANS; INFANT; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2A; NEOPLASM INVASIVENESS; ORBITAL NEOPLASMS; PARAPLEGIA; PREDNISOLONE; SAFETY;

EID: 0034133168     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-693X(00)88087-2     Document Type: Article

References (14)

1. 1 Enjolras O, Riche MC, Merland JJ, Escande JP. Management of alarming hemangiomas in infancy: a review of 25 cases. Pediatrics 1990; 85 : 491-8.
2. 2 Frieden IJ, Eichenfield LF, Esterly NB, Geronemus R, Mallory SB. Guidelines of care for hemangiomas of infancy. American Academy of Dermatology Guidelines/Outcomes Comittee. J Am Acad Dermatol 1997 ; 37 : 631-7.
3. 3 White CW, Sondheimer HM, Crouch EC, Wilson H, Fan LL. Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a. N Engl J Med 1989 ; 320 : 1197-200.
4. 4 Orchard PJ, Smith CM, Woods WG, Day DL, Dehner LP, Shapiro R. Treatment of hemangioendotheliomas with α interferon. Lancet 1989 ; ii : 565-7.
5. 5 Ezekowitz RAB, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992 ; 326 : 1456-63 (corrections : N Engl J Med 1994 ; 330 : 300 et N Engl J Med 1995 ; 333 : 595-6).
6. 6 Ohlms LA, Jones DT, McGill TJ, Healy GB. Interferon alfa-2a therapy for airways hemangiomas. Ann Otol Rhinol Laryngol 1994 ; 103 : 1-8.
7. 7 Soumekh B, Adams GL, Shapiro RS. Treatment of head and neck hemangiomas with recombinant interferon alpha-2b. Ann Otol Rhinol Laryngol 1996 ; 105 : 201-6.
8. 8 Léauté-Labrèze C, Labbé L, Grenier N, Berge J, Vergnes P, Taïeb A. Hémangiomes graves traités par interféron alpha-2b : sept cas. Ann Dermatol Vénéréol 1998 ; 125 : 174-8.
9. 9 Teillac Hamel D, De Prost Y, Bodemer C, Andry P, Enjolras O, Sebag G, et al. Serious chidhood angiomas: unsuccessful alpha-2b interferon treatment. A report of four cases. Br J Dermatol 1993 ; 129 : 473-6.
10. 10 Folkman J. Successful treatment of an angiogenic disease. N Engl J Med 1989 ; 320 : 1211-2.
11. 11 Merimsky O, Chaitchik S. Neurotoxicity of interferon-alpha. Anticancer Drugs 1992 ; 3 : 567-70.
12. 12 Rohatiner AZ, Prior P, Burton A, Balkwill F, Lister TA. Central nervous system toxicity of interferon. Prog Exp Tumor Res 1985 ; 29 : 197-202.
13. 13 Vesikari T, Nuutila A, Cantell K. Neurologic sequelae following interferon therapy of juvenile laryngeal papilloma. Acta Pediatr Scand 1988 ; 77 : 619-22.
14. 14 Barlow CF, Priebe CJ, Mulliken JB, Barnes PD, Mac Donald D, Folkman J, et al. Spastic diplegia as a complication of interferon alfa-2a treatment of hemangiomas of infancy. J Pediatr 1998 ; 132 : 527-30.